Loading...
Market
Story
Novavax, Sanofi Sign Multibillion-Dollar Deal for COVID-19 and Flu Vaccines
May 10, 2024, 07:34 AM
Novavax and Sanofi have entered into a multibillion-dollar licensing agreement to co-commercialize a COVID-19 vaccine and to develop novel combination vaccines for COVID-19 and influenza. The deal also includes Sanofi taking an equity stake in Novavax. This collaboration aims to enhance vaccine availability and efficacy against these respiratory diseases.
View original story
Similar markets
Novavax/Sanofi leads • 33%
Pfizer/BioNTech leads • 33%
Moderna leads • 33%
Novavax outperforms Sanofi • 50%
Sanofi outperforms Novavax • 50%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Approved in USA • 25%
Approved in EU • 25%
Approved in both USA and EU • 25%
Not approved in either • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Novavax • 25%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%